EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)

A Phase I Study of Nimotuzumab Combined with Irinotecan in Chinese Patients with Advanced Solid Tumors

Zhichao Jiang, Wen Zhang, Chunxia Du, Yongkun Sun, Aiping Zhou

Clinical Pharmacology in Drug Development · 2026

DOI: 10.1002/cpdd.70108 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical Pharmacology in Drug Development, 2026. Verfasst von Zhichao Jiang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department 5, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Irinotecan, Neoplasms. Die Arbeit nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nimotuzumab is an anti‐epidermal growth factor receptor antibody. This Phase I study evaluated the pharmacokinetics and safety of nimotuzumab plus irinotecan in Chinese patients with advanced solid tumors. At single ascending dosage (SAD) stage, four cohorts (100, 200, 400, and 600 mg) of patients received nimotuzumab intravenously on Day 1, alongside irinotecan 180 mg/m 2 on Day 8. Three weeks later, all patients in the four cohorts transferred to multiple ascending dosage (MAD) stage: nimotuzumab was administrated weekly for 6 weeks, alongside irinotecan (Days 1, 15, 29, 43, and 57, 180 mg/m 2 ). Primary objective was pharmacokinetics, safety and tolerability was also examined. From December 2012 to October 2014, in SAD and MAD stages, there were 28 and 39 patients with Stage IV solid tumors. The area under the concentration curve (AUC 0–∞ ) for a single dose of nimotuzumab was 10.2 ± 2.7 (100 mg), 37.6 ± 10.0 (200 mg), 114.8 ± 35.5 (400 mg), 197.6 ± 32.0 (600 mg) (×100 h µg/mL), and for multiple dose, it was 26.7 ± 3.4 (100 mg), 87.1 ± 12.0 (200 mg), 193.4 ± 46.9 (400 mg) and 446.3 ± 100.7 (600 mg) (×100 h µg/mL). There was low incidence of rash and no dose‐limiting toxicities occurred. This study indicated that nimotuzumab at doses ranging from 100 to 600 mg exhibited a manageable and tolerable safety profile.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsIrinotecanNeoplasmsAdultAgedFemaleHumansMaleMiddle AgedArea Under CurveDose-Response Relationship, DrugEast Asian People

Stichwörter der Autor:innen

advanced solid tumorsirinotecannimotuzumabpharmacokinetics

Substanzen

Antibodies, Monoclonal, HumanizedIrinotecannimotuzumab

Autor:innen und Institutionen

  • Medical Oncology Department 5, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China.

Zitieren

APA

Jiang, Z., Zhang, W., Du, C., Sun, Y., & Zhou, A. (2026). A Phase I Study of Nimotuzumab Combined with Irinotecan in Chinese Patients with Advanced Solid Tumors. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.70108

Vancouver

Jiang Z, Zhang W, Du C, Sun Y, Zhou A. A Phase I Study of Nimotuzumab Combined with Irinotecan in Chinese Patients with Advanced Solid Tumors. Clinical Pharmacology in Drug Development. 2026. doi:10.1002/cpdd.70108

BibTeX
@article{Jiang2026,
  author = {Jiang, Zhichao and Zhang, Wen and Du, Chunxia and Sun, Yongkun and Zhou, Aiping},
  title = {A Phase I Study of Nimotuzumab Combined with Irinotecan in Chinese Patients with Advanced Solid Tumors},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2026},
  doi = {10.1002/cpdd.70108}
}
Kostenlos starten →